Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Vijay Bonthapally
Patient-Reported Outcomes of Brentuximab Vedotin in Hodgkin Lymphoma and Anaplastic Large-Cell Lymphoma
OncoTargets and Therapy
Oncology
Pharmacology
Related publications
Improving Outcomes After Allogeneic Hematopoietic Cell Transplantation for Hodgkin Lymphoma in the Brentuximab Vedotin Era
Bone Marrow Transplantation
Transplantation
Hematology
A Cost-Effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Journal of Health Economics and Outcomes Research
A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed/Refractory (R/R) Systemic Anaplastic Large-Cell Lymphoma (Salcl) or R/R Hodgkin Lymphoma (Hl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey
Annals of Hematology
Medicine
Hematology
An Anaplastic T-Cell Lymphoma Mimicking Classical Hodgkin Lymphoma
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Brentuximab Vedotin Prior to Allogeneic Stem Cell Transplantation in Hodgkin Lymphoma: A Report From the EBMT Lymphoma Working Party
British Journal of Haematology
Hematology
BRENTUXIMAB VEDOTIN FOR RELAPSED HODGKIN LYMPHOMA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA WORKING PARTY
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Successful Rapid Desensitization to the Antibody–drug Conjugate Brentuximab Vedotin in a Patient With Refractory Hodgkin Lymphoma
Journal of Oncology Pharmacy Practice
Medicine
Oncology
Pharmacology
Acute Pancreatitis Following Brentuximab Vedotin Therapy for Refractory Hodgkin Lymphoma: A Case Report
Drugs in R and D
Pharmacology
